Abstract:Objective To explore the clinical application effect of remimazolam combined with tramadol in endoscopic submucosal dissection (ESD) of upper gastrointestinal tract.Methods 100 patients who underwent ESD from January 2024 to August 2025 were selected and randomly divided into the observation group (remimazolam + tramadol) and the control group (remimazolam + sufentanil) by random number table method, with 50 cases in each group. Postoperative VAS score, BIS value range maintenance rate, extubation time, adverse reactions and overall clinical outcomes were compared between the two groups.Results The rate of low VAS scores in patients of the observation group at 3 h, 6 h, 12 h and 24 h postoperatively was higher than that in the control group (P < 0.05); The proportion of time that bispectral index (BIS) values stayed within the range of 45 - 60 in the observation group was higher than that in the control group (P < 0.05); The postoperative extubation time of patients in the observation group was shorter than that in the control group (P < 0.05); The total incidence of adverse reactions in the observation group was lower than that in the control group (P < 0.05); The excellent and good rate in the observation group was higher than that in the control group (P < 0.05).Conclusion Remimazolam combined with tramadol can achieve better analgesia and sedation, shorten the recovery time, and reduce the adverse reactions in ESD of upper gastrointestinal tract, which has good clinical application value.